Monoclonal antibodies for treatment of cancer

US8961980B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugar Sahin · Mainz, DE
• Michael Koslowski · Mainz, DE
• Ozlem Tureci · Homburg, DE

Key dates

• Filing date: Dec 11, 2012
• Grant date: Feb 24, 2015
• Expiry date: Dec 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.